scholarly journals The economic impact of rapid Candida species identification by T2Candida among high-risk patients

2015 ◽  
Vol 10 (7) ◽  
pp. 1133-1144 ◽  
Author(s):  
Sara Pinar Bilir ◽  
Cheryl P Ferrufino ◽  
Michael A Pfaller ◽  
Julie Munakata
Keyword(s):  
High Risk ◽  
Economic Impact ◽  
Species Identification ◽  
Candida Species ◽  
High Risk Patients ◽  
Risk Patients

Abstract P240: Economic Impact of Major Adverse Cardiac Events (MACE) in Individuals Undergoing Invasive Cardiac Catheterization Procedures (CCP) With Low or Iso-Osmolar Contrast Agents

2011 ◽  
Vol 4 (suppl_1) ◽  
Author(s):  
Brian Meissner ◽  
James Spalding
Keyword(s):  
High Risk ◽  
Contrast Media ◽  
Economic Impact ◽  
Resource Utilization ◽  
Cardiac Catheterization ◽  
Cardiac Events ◽  
Post Discharge ◽  
High Risk Patients ◽  
Iodinated Contrast ◽  
Risk Patients

Objective: To assess the economic impact of MACE during cardiac catheterization procedures in both high and low risk patients and to apply literature estimates of MACE rates the iso-osmolar iodinated contrast media iodixanol versus low-osmolar contrast media (LOCM). Methods: We performed a retrospective analysis using the Premier Perspective™ database, which contains patient-level data including primary and secondary diagnosis and procedure codes. Inpatient adults without prior hemodialysis who underwent invasive cardiac catheterization procedures with contrast media during 2007-2008 were studied. MACE was defined as acute MI, ischemic heart disease, or angina. Resource utilization, re-admittance rate, length of stay (LOS), and cost were collected. High-risk patients were defined as have an AMI or angina as the admitting diagnosis. Aggregate MACE outcomes were then applied to MACE rates from multi-center studies found in the literature comparing iodixanol to LOCM. Results: Among 521,437 patients in the Premier Perspective™ undergoing CCP, 13,149 (2.52%) experienced a MACE. Of those experiencing MACE, high-risk patients had longer LOS, 4.2 vs. 3.3 days, p <0.0001, longer ICU LOS. 2.6 vs. 2.3 days, p= 0.0028, greater total costs, $15,020 vs. $12,413, p <0.0001, and a greater frequency of MACE readmission due to re-catheterization, 58.66% vs. 50.68%, p= <0.0001. For readmissions within 30 days post-discharge, LOS and cost remained statistically significant for high-risk patients, but ICU LOS was not significantly different. In applying literature-based MACE rates, isosmolar iodixanol versus LOCM iopamidol potentially saves on average $600 per patient in inpatient MACE-related costs but no difference for 30 days post-discharge MACE. Additionally, iodixanol may save up to $616 on average per patient vs. Ioxaglate in high-risk inpatient MACE-related costs, but no difference in non high-risk patients. Conclusions: MACE is a complication in CCP with substantial resource utilization, cost, and mortality associated with it. The iso-osmolar contrast agent iodixanol may reduce the rate of MACE in certain instances and therefore reduce the MACE-related cost and resource utilization associated with cardiac catheterization procedures.

scholarly journals Susceptibilities of Candida Species Isolated from the Lower Gastrointestinal Tracts of High-Risk Patients to the New Semisynthetic Echinocandin LY303366 and Other Antifungal Agents

1998 ◽  
Vol 42 (9) ◽  
pp. 2446-2448 ◽  
Author(s):  
George G. Zhanel ◽  
James A. Karlowsky ◽  
Sheryl A. Zelenitsky ◽  
Michael A. Turik ◽  
Daryl J. Hoban
Keyword(s):  
Candida Albicans ◽  
High Risk ◽  
Candida Species ◽  
Candida Glabrata ◽  
Antifungal Agents ◽  
High Risk Patients ◽  
Risk Patients ◽  
Stool Specimens

ABSTRACT Fifty-two percent of stool specimens collected from 1,200 high-risk patients were colonized with yeasts, primarily Candida albicans (53.6%) and Candida glabrata (35.7%). Susceptibilities to all antifungal agents tested, including LY303366, were similar to those reported previously forCandida species isolated from blood.

Combination of norfloxacin and cisapride in prevention of SBP in high risk patients: A new approach

2001 ◽  
Vol 120 (5) ◽  
pp. A376-A376
Author(s):  
B JEETSANDHU ◽  
R JAIN ◽  
J SINGH ◽  
M JAIN ◽  
J SHARMA ◽  
...  
Keyword(s):  
High Risk ◽  
New Approach ◽  
High Risk Patients ◽  
Risk Patients

1610: High-Risk Patients Undergoing Radical Prostatectomy Today are Less High-Risk than in the Past

2005 ◽  
Vol 173 (4S) ◽  
pp. 436-436
Author(s):  
Christopher J. Kane ◽  
Martha K. Terris ◽  
William J. Aronson ◽  
Joseph C. Presti ◽  
Christopher L. Amling ◽  
...  
Keyword(s):  
High Risk ◽  
Radical Prostatectomy ◽  
High Risk Patients ◽  
The Past ◽  
Risk Patients

995: Immunohistochemical Analysis of Tumor Polyamines Discriminates High Risk Patients Undergoing Nephrectomy for Renal Cell Carcinoma

2004 ◽  
Vol 171 (4S) ◽  
pp. 263-263
Author(s):  
Nathalie Rioux-Leclercq ◽  
Florence Jouan ◽  
Pascale Bellaud ◽  
Jacques-Philippe Moulinoux ◽  
Karim Bensalah ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
High Risk ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Immunohistochemical Analysis ◽  
High Risk Patients ◽  
Risk Patients
Sign in / Sign up

Export Citation Format

Share Document